The deal range was $5.00-$5.25. JPMorgan and Leerink acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
- Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Wave Life Sciences reports Q3 EPS 7c, consensus (18c)